The systemic inflammatory response in heart failure

Progress in Pediatric Cardiology

Volumn 11, Issue 3, 2000, Pages 219-230

  Anderson, Michael R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Inflammation; NF B, Nitric oxide; Pediatric heart failure; Systemic inflammatory response syndrome; Tumor necrosis factor

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

EXERCISE TOLERANCE; HEART FAILURE; HEART OUTPUT; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0033823272     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(00)00053-9     Document Type: Article

References (45)

1. De Keulenaer G.W., Brutsaert D.L. Pathogenesis of heart failure. Changing conceptual paradigms. Acta Cardiol. 53:1998;131.
2. Bone R.C. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 24:1996;163.
3. Glauser M.P. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs. 52(Suppl 2):1996;9-17.
4. Schafer R., Sheil J.M. Superantigens and their role in infectious disease. Adv Pediatr Infect Dis. 369:1995;10-90.
5. Tracey K.J., Cerami A. Tumor necrosis factor in septic shock. Neugebauer E.A., Holaday J.A. Handbook of mediators in septic shock. 1993;291-308 CRC Press, Boca Raton.
6. Anderson M.R., Blumer J.L. Advances in the therapy for sepsis in children. Pediatr Clin North Am. 44:1997;179.
7. Tracey K.J., Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med. 21:1993;S415.
8. Shapiro L., Clark B.D., Orencole S.F., Poutsiaka D.D., Granowitz E.V., Dinarello C.A. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis. 167:1993;1344.
9. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236.
10. Meldrum D.R., Meng X., Dinarello C.A. et al. Human myocardial tissue TNFalpha expression following acute global ischemia in vivo. J Mol Cell Cardiol. 30:1998;1683.
11. Ferrari R., Bachetti T., Confortini R. et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure [see comments]. Circulation. 92:1995;1479.
12. Nozaki N., Yamaguchi S., Yamaoka M., Okuyama M., Nakamura H., Tomoike H. Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. J Mol Cell Cardiol. 30:1998;2003.
13. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753.
14. Natanson C., Eichenholz P.W., Danner R.L. et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 169:1989;823.
15. Bozkurt B., Kribbs S.B., Clubb F.J.J. et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382.
16. Nakano M., Knowlton A.A., Dibbs Z., Mann D.L. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 97:1998;1392.
17. Vincent J.L., Bakker J., Marecaux G., Schandene L., Kahn R.J., Dupont E. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest. 101:1992;810.
18. Abraham E., Wunderink R., Silverman H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. J Am Med Assoc. 273:1995;934.
19. Abraham E., Glauser M.P., Butler T. et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. J Am Med Assoc. 277:1997;1531.
20. Spitzer J.A. Interleukins in sepsis. Neugebauer E.A., Holaday J.A. Handbook of mediators in septic shock. 1993;279-289 CRC Press, Boca Raton.
21. Okusawa S., Gelfand J.A., Ikejima T., Connolly R.J., Dinarello C.A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 81:1988;1162.
22. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 98:1998;149.
23. Shioi T., Matsumori A., Kihara Y. et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 81:1997;664.
24. Francis S.E., Holden H., Holt C.M., Duff G.W. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 30:1998;215.
25. Fisher C.J.J., Slotman G.J., Opal S.M. et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open- label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group [see comments]. Crit Care Med. 22:1994;12.
26. Fisher C.J.J., Dhainaut J.F., Opal S.M. et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group [see comments]. J Am Med Assoc. 271:1994;1836.
27. Lee J.I., Burckart G.J. Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol. 38:1998;981.
28. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1997;1066.
29. Ritchie M.E. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation. 98:1998;1707.
30. Wong S.C., Fukuchi M., Melnyk P., Rodger I., Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure [see comments]. Circulation. 98:1998;100.
31. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002.
32. Sawyer D.B., Colucci W.S. Nitric oxide in the failing myocardium. Cardiol Clin. 16:1998;657.
33. Hare J.M., Loh E., Creager M.A., Colucci W.S. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation. 92:1995;2198.
34. Iwasaki A. et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis [in process citation]. J Am Coll Cardiol. 33:1999;1400.
35. Haywood G.A., Tsao P.S., von der L. et al. Expression of inducible nitric oxide synthase in human heart failure [see comments]. Circulation. 93:1996;1087.
36. Vejlstrup N.G., Bouloumie A., Boesgaard S. et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 30:1998;1215.
37. Drexler H., Kastner S., Strobel A., Studer R., Brodde O.E., Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol. 32:1998;955.
38. Harding S.E., Davies C.H., Money-Kyrle A.M., Poole-Wilson P.A. An inhibitor of nitric oxide synthase does not increase contraction or beta-adrenoceptor sensitivity of ventricular myocytes from failing human heart. Cardiovasc Res. 40:1998;523.
39. Feldman A.M., Bristow M.R., Parmley W.W. et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group [see comments]. N Engl J Med. 329:1993;149.
40. Matsumori A., Shioi T., Yamada T., Matsui S., Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 89:1994;955.
41. Matsumori A., Ono K., Sato Y., Shioi T., Nose Y., Sasayama S. Differential modulation of cytokine production by drugs: implications for therapy in heart failure. J Mol Cell Cardiol. 28:1996;2491.
42. Bergman M.R., Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors [published erratum appears in J Pharmacol Exp Ther 1997;280(1):520]. J Pharmacol Exp Ther. 279:1996;247.
43. Matsui S., Matsumori A., Matoba Y., Uchida A., Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest. 94:1994;1212.
44. Matsumori A., Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy - lessons from animal experiments. Eur Heart J (Suppl O). 16:1995;140-143.
45. Feldman AM, Young J, Bourge R et al. Mechanism of increased mortality from vesnarinone in the Severe Heart Trial (VesT) [Abstract], J Am Coll Cardiol 1997;29.